Akamis Bio Limited

Akamis Bio Limited, based in the US, specializes in Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics, focusing on innovative cancer treatments that engage the immune system to target solid tumors. Founded in 2010 in Cambridge, US, Akamis Bio Limited focuses on developing T-SIGn® therapeutics for cancer treatment. The company recently secured USD 60. 00 mn in Series A funding, led by Sedgwick Yard, to advance its clinical trials.

The CEO is Howard Davis, and the founder is Kerry Fisher, who has a history of founding other ventures. Akamis Bio has conducted 9 deals to date, with the latest deal occurring on December 17, 2024, raising a total of USD 0. 30 mn. Akamis Bio specializes in Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics, with its primary product, NG-350A, currently in Phase 1b clinical trials.

This immuno-stimulatory tumor gene therapy promotes intratumoral expression of a CD40 agonist monoclonal antibody, aiming to help the immune system recognize and eliminate cancer cells in various solid tumors. The company primarily serves patients in the US and the UK, focusing on enhancing antitumor immune responses within the tumor microenvironment through intravenous delivery. In 2023, Akamis Bio reported a revenue of USD 1,295,925. 40 and an EBITDA of USD -28,628,772.

80. The revenue model is centered on the development and commercialization of its T-SIGn® therapeutics, leveraging partnership agreements and clinical collaborations to generate income through milestone payments, royalties, and licensing agreements. In December 2024, following the successful raising of USD 60. 00 mn in Series A funding, Akamis Bio plans to utilize these funds to support the next phase of its clinical trials specifically targeting patients with rectal cancer.

The company aims to enhance its product pipeline and expand its reach into new markets, with a strategic focus on collaboration with healthcare providers and institutions to advance its innovative cancer therapies.